What the FDA Approved
The FDA granted accelerated approval to Etcamah (camizestrant), an estrogen receptor antagonist, for use with one of three CDK4/6 inhibitors: abemaciclib, palbociclib or ribociclib.
The treatment is for certain patients with ER-positive, HER2-negative advanced or metastatic breast cancer whose tumors develop an ESR1 mutation while they are receiving an aromatase inhibitor with a CDK4/6 inhibitor.
ESR1 mutations can emerge as cancers adapt to treatment. According to the FDA, fewer than 5% of patients have these mutations when HR-positive metastatic breast cancer is first diagnosed, but the proportion can rise to about 40% to 50% after progression on an aromatase inhibitor.
Why ESR1 Mutations Matter
Cancer can change while it is being treated.
A therapy that initially keeps a tumor under control may become less effective as the cancer develops new resistance mechanisms. ESR1 mutations are one way this can happen.
What makes this approval unusual is when doctors can act.
Instead of waiting for conventional imaging to show that the cancer has progressed, doctors can look for the resistance mutation in tumor DNA circulating in the patient's blood.
The FDA described Etcamah as the first cancer therapy approved based on detecting a resistance mutation in circulating tumor DNA before imaging shows disease progression.
The Trial Behind the Approval
The FDA based its decision on the SERENA-6 clinical trial, involving 315 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer and detectable ESR1 mutations.
Patients either switched from their aromatase inhibitor to camizestrant while continuing a CDK4/6 inhibitor, or continued their existing aromatase inhibitor plus CDK4/6 inhibitor treatment.
The difference was substantial.
Median progression-free survival was 16 months with camizestrant compared with 9.2 months for patients who continued the aromatase inhibitor.
Overall survival data were not yet mature at the time of the analysis supporting the approval.
A Blood Test Can Spot the Mutation
The FDA also approved Guardant360 CDx as a companion diagnostic for identifying eligible patients with ESR1 mutations.
The test analyzes circulating tumor DNA, or ctDNA — small pieces of DNA shed by cancer cells into the bloodstream.
That creates an intriguing possibility: doctors may be able to detect an important molecular sign of treatment resistance before progression becomes visible on a scan.
There Is an Important Catch
Etcamah received accelerated approval, meaning an important question still needs to be answered.
The FDA says it has not yet been confirmed whether switching treatment when an ESR1 mutation appears, rather than waiting for confirmed disease progression, translates into a clinically meaningful benefit.
Confirmatory studies are required to verify and further describe that benefit, and continued approval may depend on those results.
Safety Information
Etcamah's prescribing information includes a boxed warning concerning the risk of irregular heart rhythm when it is taken with certain other medicines.
The labeling also includes warnings and precautions involving abnormally slow heart rate and potential harm to an unborn baby.
Patients and healthcare professionals should consult the FDA-approved prescribing information when making treatment decisions.
Why This Approval Is Interesting
The bigger story isn't simply another breast cancer drug.
It is the possibility of cancer treatment becoming more responsive to what a tumor is doing in real time.
Instead of relying only on scans, molecular information circulating in the blood can reveal how a cancer is changing and potentially help doctors adjust treatment earlier.
For eligible patients with advanced breast cancer, Etcamah adds another treatment option. But the longer-term clinical benefit of making that switch before imaging confirms progression still needs to be established.
The FDA granted the accelerated approval to AstraZeneca.